Clinical value of vascular endothelial growth factor combined with interferon-γ in diagnosing malignant pleural effusion and tuberculous pleural effusion

Abstract

In order to investigate the clinical value of vascular endothelial growth factor (VEGF) combined with interferon-γ (IFN-γ) in diagnosing malignant pleural effusion and tuberculous pleural effusion, 42 cases of malignant pleural effusion and 45 cases of tuberculous pleural effusion in Tongji Hospital, from March 2004 to May 2005, were included. The carcinoembryonic antigen (CEA), VEGF and IFN-γ levels of pleural effusion were detected by using ELISA, and adenosine deaminase (ADA) activity was determined by using enzyme kinetic analytical method. The sensitivity, specificity, accuracy and area under the curve (AUC^ROC) of CEA and VEGF, VEGF/IFN-γ ratio, ADA and IFN-γ were measured by receiver operating characteristic curve (ROC). The results showed that CEA, VEGF levels and VEGF/IFN-γ ratio were significantly higher and the ADA and IFN-γ levels were significantly lower in malignant group than those in tuberculous group (P<0.01). The sensitivity, specificity, accuracy and AUC^ROC of VEGF/IFN-γ ratio (88.7%, 99.8%, 94.4%, 0.96 respectively) were higher than those of CEA (67.8%, 96.1%, 82.4%, 0.78 respectively) and VEGF (81.5%, 84.3%, 82.9%, 0.79 respectively). The sensitivity, specificity, accuracy and AUC^ROC of IFN-γ (85.7%, 96.4%, 90.9%, 0.94 respectively) were higher than those of ADA (80.2%, 87.6%, 83.8%, 0.81 respectively). It was concluded that VEGF/IFN-γ ratio and IFN-γ could be used as valuable parameters for the differential diagnosis of malignant pleural effusion and tuberculous pleural effusion.

Keywords

vascular endothelial growth factor / interferon-γ / malignant pleural effusion / tuberculous pleural effusion

References

[1] HamedE. A., El-NoweihiA. M., MohamedA. Z., et al.. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology, 2004, 9(1): 81-86

[2] LiY. H., XieC. M.. Advanced study in pathogenesis of tuberculous pleuritis. Guowei Yixue Neikexue Fence (Chinese), 2002, 29(9): 373-376

[3] VerheulH. M., HoekmanK., JornaA. S., et al.. Targeting vascular endothelial growth factor blockade: ascites and pleural effusions formation. Oncologist, 2000, 5(Suppl1): 45-50

[4] YanoS., HerbstR. S., ShinoharaH., et al.. Treatment for malignant pleural effusions of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res, 2000, 6(3): 957-965

[5] HirakiA., AoeK., MatsuoK., et al.. Simultaneous measurement of T-helper 1 cytokines in tuberculous pleural effusion. Int J Tuberc Lung Dis, 2003, 7(12): 1172-1177